High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score

Arthritis and Rheumatism

Volumn 63, Issue 7, 2011, Pages 2007-2013

  Bulatović, Maja ^a   Heijstek, Marloes W ^a   Verkaaik, Marleen ^a   Van Dijkhuizen, E H Pieter ^a   Armbrust, Wineke ^b   Hoppenreijs, Esther P A ^c   Kamphuis, Sylvia ^d   Kuis, Wietse ^a   Egberts, Toine C G ^a   Sinnema, Gerben ^a   Rademaker, Carin M A ^a   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ABDOMINAL PAIN; ARTICLE; BEHAVIOR DISORDER; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL FEATURE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG TOXICITY; FEMALE; HUMANS; MALE; METHOTREXATE; QUESTIONNAIRES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 79959836350     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30367     Document Type: Article

References (20)

1. Ravelli A, Martini A,. Juvenile idiopathic arthritis. Lancet 2007; 369: 767-78.
2. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303: 1266-73.
3. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, De Oliveira SK, Falcini F, et al, for the Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-201. (Pubitemid 38924397)
4. Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2501-6. (Pubitemid 39603104)
5. Murray KJ, Lovell DJ,. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002; 16: 361-78.
6. Van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G,. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 2007; 25: 480-5. (Pubitemid 47091030)
7. Alarcon GS, Morgan SL,. Folinic acid to prevent side effects of methotrexate in juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 2184-5. (Pubitemid 27006776)
8. Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A,. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999; 17: 625-7. (Pubitemid 29454838)
9. Van Ede AE, Laan RF, Rood MJ, Huizinga TW, Van De Laar MA, Van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-24. (Pubitemid 32651731)
10. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-93.
11. Figueroa-Moseley C, Jean-Pierre P, Roscoe JA, Ryan JL, Kohli S, Palesh OG, et al. Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw 2007; 5: 44-50. (Pubitemid 46212276)
12. Dolgin MJ, Katz ER, McGinty K, Siegel SE,. Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics 1985; 75: 547-52. (Pubitemid 15144673)
13. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2. (Pubitemid 38160763)
14. Brunner HI, Johnson AL, Barron AC, Passo MH, Griffin TA, Graham TB, et al. Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol 2005; 11: 194-204. (Pubitemid 41134329)
15. Hashkes PJ, Laxer RM,. Medical treatment of juvenile idiopathic arthritis. JAMA 2005; 294: 1671-84. (Pubitemid 41407360)
16. Ramanan AV, Whitworth P, Baildam EM,. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003; 88: 197-200. (Pubitemid 36269497)
17. Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN,. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31: 179-82. (Pubitemid 38067542)
18. Duff AJ,. Incorporating psychological approaches into routine paediatric venepuncture. Arch Dis Child 2003; 88: 931-7. (Pubitemid 37194055)
19. Hornby PJ,. Central neurocircuitry associated with emesis. Am J Med 2001; 111 Suppl 8A: 106S-12S. (Pubitemid 34032001)
20. Veyrat-Follet C, Farinotti R, Palmer JL,. Physiology of chemotherapy-induced emesis and antiemetic therapy: predictive models for evaluation of new compounds. Drugs 1997; 53: 206-34. (Pubitemid 27073113)